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Abstract
Mephedrone (4-methylmethcathinone, MMC) is a popular recreational drug, yet its potential harms are yet to be fully
established. The current study examined the impact of single or repeated MMC exposure on various neurochemical and
behavioral measures in rats. In Experiment 1 male adolescent Wistar rats received single or repeated (once a day for 10 days)
injections of MMC (30 mg/kg) or the comparator drug methamphetamine (METH, 2.5 mg/kg). Both MMC and METH caused
robust hyperactivity in the 1 h following injection although this effect did not tend to sensitize with repeated treatment.
Striatal dopamine (DA) levels were increased 1 h following either METH or MMC while striatal and hippocampal serotonin
(5-HT) levels were decreased 1 h following MMC but not METH. MMC caused greater increases in 5-HT metabolism and
greater reductions in DA metabolism in rats that had been previously exposed to MMC. Autoradiographic analysis showed
no signs of neuroinflammation ([125I]CLINDE ligand used as a marker for translocator protein (TSPO) expression) with
repeated exposure to either MMC or METH. In Experiment 2, rats received repeated MMC (7.5, 15 or 30 mg/kg once a day
for 10 days) and were examined for residual behavioral effects following treatment. Repeated high (30 mg/kg) dose MMC
produced impaired novel object recognition 5 weeks after drug treatment. However, no residual changes in 5-HT or DA
tissue levels were observed at 7 weeks post-treatment. Overall these results show that MMC causes acute but not lasting
changes in DA and 5-HT tissue concentrations. MMC can also cause long-term memory impairment. Future studies of
cognitive function in MMC users are clearly warranted.
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Introduction
Mephedrone (‘‘Meow’’, 4-methylmethcathinone, MMC) is a
substituted cathinone that has rapidly gained popularity over
recent years as a recreational drug [1,2,3]. The cathinones display
pharmacological properties that closely resemble slightly less
potent equivalents of their amphetamine analogs [4]. Users of
MMC report effects that are reminiscent of methamphetamine
(METH: stimulant, euphoric), cocaine (‘‘moreish’’, propensity to
cause binges) and 3,4-methylenedioxymethamphetamine
(MDMA: entactogenic, prosocial) [5,6,7]. Studies of MMC are
at a formative stage with the neurochemical actions and toxicity
underexplored relative to the widespread use of the drug.
Our group recently characterized the activational ‘‘signature’’ of
MMC (30 mg/kg) in the brain relative to METH (2 mg/kg) in
adolescent rats using Fos immunohistochemistry [8]. Consistent
with the subjective reports of users, the Fos ‘‘signature’’ of MMC
resembled a combination of METH and MDMA. This analysis is
also supported by recent microdialysis results indicating that low
doses of MMC (1–3 mg/kg) cause a robust amphetamine-like
increase in dopamine (DA) and a profound MDMA-like increase
in 5-hydroxytryptamine (5-HT) in the nucleus accumbens [9].
Consistent with these observations, recent in vitro studies indicate
that MMC has affinity for both the 5-HT transporter (SERT) and
DA transporter (DAT) and inhibits striatal synaptosomal DA
uptake (like METH) and hippocampal synaptosomal 5-HT uptake
(like MDMA) [10,11,12]. A substantial serotonergic effect of
MMC is also indicated by clinical evidence of the ‘‘serotonin
syndrome’’ in some MMC users [13].
Overall, there is only sparse evidence regarding the possible
harms arising from MMC use. Clinical reports suggest users
occasionally suffer from agitation, tachycardia, hypertension and
seizures [14,15,16,17,18]. However, in almost all reports, sedation
and symptomatic treatment allows patients to be discharged in a
fairly short time (typically within hours) without obvious lasting ill
effects. While a number of deaths have been linked to MMC
[18,19,20,21,22], there are few in which a causal role for MMC
has been unequivocal.
Information on long-term harms is largely limited to anecdotal
reports of cognitive impairment and mood disturbance in on-line
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discussion sites such as Drugs-Forum, Bluelight and Erowid. Although
only a handful of peer-reviewed investigations into potential
MMC-induced harms have been published to date, these have
largely failed to demonstrate lasting impairment. MMC does not
appear to cause dopaminergic neurotoxicity in mice [23], nor does
it induce a lasting impairment of cardiac function in rats [24]. Rats
given moderate doses of MMC (3610 mg/kg, S.C., once every
2 h) showed no alteration in levels of cortical or striatal
noradrenaline, DA or 5-HT when measured two weeks later [12].
However, two recent publications do give some cause for
concern. Repeated high doses of MMC (4610 or 4625 mg/kg,
I.P., once every 2 h), paired with elevated ambient temperatures
($27uC), depleted 5-HT when measured 7 days later in rats [10].
This is an effect reminiscent of that seen with high doses of
MDMA in laboratory animals [25,26,27,28], although controversy
continues as to the significance of such effects for humans [12,29].
It is unknown whether the 5-HT depletion reported in rats
following binge dosing with MMC is permanent. Secondly,
recently published work by Freeman et al. [30] is suggestive of
lasting cognitive impairment (as measured by a prose recall task) in
human MMC users.
In the present study we therefore sought to clarify whether
lasting decreases in regional levels of 5-HT or DA occurred
following exposure to MMC in rats and to investigate the
possibility that this treatment may induce lasting cognitive
impairment. Our previous research has documented cognitive
and social impairment in rats weeks or months after relatively brief
exposure to drugs such as MDMA and METH
[25,27,28,31,32,33]. These effects are consistent with reports from
other groups [34,35,36,37].
Autoradiographic analysis was also performed in the present
study. The ligand [125I]CLINDE [38,39] was used to quantify
levels of translocator protein (TSPO) in rats repeatedly exposed to
MMC or METH. TSPO receptors display upregulation with
neurodegeneration, concurrent with the microglial activation
observed during neuroinflammatory processes [40]. As inflamma-
tory responses may play an important role in the toxic potential of
several drugs of abuse [40,41,42,43], it was of interest to test
whether MMC exposure induced this response.
Finally, it was of interest to determine whether repeated
exposure to MMC causes sensitization, an effect sometimes
reported with MDMA and METH, whereby the neurochemical
and behavioral response to the drug is augmented with repeated
administration [44,45,46]. We therefore compared the acute
behavioral (locomotor hyperactivity) and neurochemical (regional
DA and 5-HT) response to MMC in rats receiving their first or
tenth dose of the drug.
Experimental Procedures
Subjects
Experiment 1 used 40 adolescent male Wistar rats (aged 3–4
weeks at delivery to our facility; mean weight on delivery 113 g)
obtained from the University of Adelaide. Experiment 2 used 48
adolescent male Wistar rats (aged approximately 3 weeks at
delivery; mean weight on delivery 126 g) sourced from the Animal
Resources Centre (Perth, Western Australia). Rats were housed in
groups of eight in large plastic tubs in a temperature-controlled
colony room (2262uC) on a 12 h light/dark cycle (lights on from
8:00 PM to 8:00 AM). Rats were acclimatized to their new
surroundings for several days before commencing a program of
handling and habituation. They were provided with food and
water ad libitum. All behavioral testing occurred during the dark
cycle. All efforts were made to minimize both the number of rats
used and distress to the rats involved. All experimentation was
approved by the University of Sydney Animal Ethics Committee
(ethics protocol L29/5-2010/3/5330).
Drugs and Doses
MMC was obtained from the U.K. Customs Service, sourced
from seizures made shortly after the banning of MMC in that
country (April 2010). The customs-sourced MMC was analysed by
High Performance Liquid Chromatography (HPLC) performed
on a Waters 2695 Separations module equipped with the Waters
Alliance Series Column Heater (set at 32uC) and Waters 2996
Photodiode Array (PDA) Detector. Samples were resolved on a
Waters XBridge C18 5 mm column (2.16150 mm) using an
isocratic flow of 30 v/v% aqueous acetonitrile with 0.1 v/v%
triethylamine at a flowrate of 0.2 mL/min. Chromatograms were
extrapolated at a UV maximum of 258 nm with data acquisition
and processing performed with the Waters Empower 2 software.
Samples were analysed in triplicate.
Reference-grade METH was obtained from the National
Measurement Institute (New South Wales, Australia). All drugs
were dissolved in physiological saline and injected I.P. at a volume
of 1 ml/kg. The dose of MMC used in Experiment 1 (30 mg/kg)
was taken from our recent study [8] in which it produced robust
hyperactivity and brain activation without any apparent adverse
consequences to the health of the rats. The dose of METH
selected (2.5 mg/kg) was slightly higher than was used in this
earlier study (2 mg/kg) as we found METH hyperactivity at
2 mg/kg in adolescent rats to be considerably below that seen with
MMC (30 mg/kg) [8].
In Experiment 2 a range of MMC doses were utilized (7.5, 15
and 30 mg/kg, injected I.P. once every day for 10 days) to
determine possible long-term adverse consequences of repeated
lower doses of MMC, similar to those we have found with
relatively low doses of MDMA [27,28,33].
Experiment 1: Effects of Acute and Repeated METH and
MMC on Locomotor Activity, DA and 5-HT
Procedure. Five days after delivery rats were divided into five
groups (VEH, METH61, METH610, MMC61, MMC610)
with n= 8 per group. All rats were injected once per day for 10
consecutive days. VEH animals received 0.9% saline injections
each day while METH61 and MMC61 rats received saline
injections for the first 9 days and an injection of METH (2.5 mg/
kg) or MMC (30 mg/kg) respectively on the 10th day. METH610
and MMC610 animals received injections of METH (2.5 mg/kg)
or MMC (30 mg/kg) respectively on each of the 10 days.
On the first and final test days, individual rats were removed
from their home cage and injected before being immediately
placed into locomotor testing chambers. Rats had been previously
acclimatized to the test chambers for 2 days prior to the day 1 test.
On each of these days, rats were treated identically to the first
dosing day except that they received vehicle injections rather than
drug doses. The order of testing was counterbalanced across
treatment conditions in order to control for time of day effects.
Ambient temperature was approximately 26uC throughout the
locomotor activity testing sessions. At 1 h after their final drug
treatment rats were rapidly decapitated and their brains removed.
HPLC analysis of striatal and hippocampal neurotransmitters was
carried out as described below.
Apparatus. Locomotor activity was assessed in dark enclosed
chambers (60 cm length626 cm depth633 cm height) with red
perspex lids located in a room dimly illuminated by a 40 W red
bulb. The floor of each chamber consisted of metal rods and the
chambers were fitted with a miniature overhead infrared video
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camera connected to a PC that used automated video tracking
software (TRACKMATE 1.0, Motion Mensura, Cooks Hill,
NSW, Australia) to determine the locomotor activity (distance
travelled) of the rat.
Neurotransmitter and metabolite analysis. HPLC meth-
ods were as described previously [27]. Brains were first sagitally
bisected, with one hemisphere set aside for autoradiography
analysis. The remaining hemispheres were manually dissected
over dry ice into five regions of interest and snap frozen in liquid
nitrogen, and then stored at 280uC until analysis. Tissue samples
from striatum and hippocampus were weighed and homogenized
in 500 ml of 0.2 M perchloric acid containing 0.1% cysteine and
400 nM of internal standard (5-hydroxy-N-methyltryptamine; 5-
HMeT) using a glass-Teflon homogenizer and Brinkman polytron.
The homogenate was then centrifuged for 15 min at 15,000 g,
4uC and pellet discarded. A 10 ml aliquot was then analysed for
bioamine content using HPLC with electrochemical detection.
Briefly, the HPLC system consisted of a Shimadzu ADvp
module (Kyoto, Japan) equipped with SIL-10 autoinjector with
sample cooler and LC-10 on-line vacuum degassing solvent
delivery unit. Chromatographic control, data collection and
processing were carried out using Shimadzu Class VP data
software. The mobile phase consisted of 0.1 mol/l phosphate
buffer (pH 3.0), PIC B-8 octane sulphonic acid (0.74 mmol/l;
Waters, Australia), sodium EDTA (0.3 mmol/l) and methanol
(18% v/v). The flow rate was maintained at 0.7 ml/min.
Chromatographic separation of DA, dihydroxyphenylacetic
acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindolacetic
acid (5-HIAA) and 5-HT were accomplished on a Phenomenex
Synergi Polar-RP 80A (25064.6, 4 mm) column maintained at
30uC. Quantification was achieved via an INTRO electrochem-
ical detector (Antec Leyden, Netherlands) equipped with Faraday-
shielded oven compartment and a glassy carbon working electrode
set at +0.75 V. The concentrations of unknown samples were
obtained from the linear regression equation of calibration curves
by plotting concentration versus area ratio of the external standard
and internal standard. HVA+DOPAC/DA ratios were used as an
index of DA metabolism, while 5-HIAA/5-HT ratios were used
for 5-HT metabolism.
Autoradiography. Autoradiographic analysis was only con-
ducted on the repeatedly dosed rats in Experiment 1. Due to the
exploratory nature of the study and the expense of autoradio-
graphic techniques the analysis was limited to those experimental
conditions most likely to produce a clear result (i.e. maximal doses
and shortest time between dosing and analysis).
Brains were rapidly removed and one hemisphere was dissected
for HPLC analysis (see above) while the other was snap-frozen
whole in liquid nitrogen and stored at 280uC. Sagittal sections
(20 mm) of the intact hemisphere were cut on a cryostat, and
mounted onto polysine-coated slides (LabServ, Australia).
[125I]CLINDE was used to assess binding density for TSPO as
described previously [38]. TSPO binding was assessed in the
hippocampus, substantia nigra, anterior thalamus, olfactory
tubercle, striatum and nucleus accumbens.
Air dried slides were either apposed against Kodak Biomax MR
film, developed, and films acquired through a BioRad GS-800
densitometer, or apposed against FujiFilm SR phosphorimaging
plates and read in a FujiFilm FLA7000 phosphorimager system.
Images were analysed using ImageJ software (NIH, USA).
Standard curves were calculated for conversion of optical density
to nCi/mg radioactivity concentration using calibrated 14C
microscales (American Radiochemical Company, USA).
Experiment 2: Long-term Residual Effects of MMC
Experiment 2 involved 4 groups of rats (VEH, MMC7.5,
MMC15, MMC30) with n= 12 per group. Beginning 4 days after
delivery to the colony (age 22–27 days) all rats were dosed once per
day for ten consecutive days with either vehicle or MMC (7.5, 15
or 30 mg/kg). Dosing was conducted in the colony room, with all
rats being weighed immediately prior to dosing. Following
injection they were returned to their home cages. The sequence
of behavioral testing used in this experiment to assess residual
effects of MMC dosing is shown in Table 1.
Behavioral Tests. Elevated Plus Maze. This test was
conducted 11 days after the conclusion of dosing. As described
previously [47] the apparatus consisted of a red perspex maze
(floored with black laminate) with two open arms (50 6 10 cm)
and two opposite closed arms (506 10 cm) that had 40 cm high
walls. The open and closed arms were connected by a central
square (10610 cm). The maze was elevated to a height of 70 cm.
The testing room was illuminated by a red light (40 W). Rats were
placed in the centre of the apparatus, with their head facing a
closed arm. Testing continued for 5 min during which time spent
on the open and closed arms and the distance travelled was
assessed using automated video tracking software (TRACKMATE
1.0, Motion Mensura, Cook’s Hill, NSW, Australia). In between
each test session the maze was thoroughly wiped down with a
damp cloth containing an ethanol solution.
Social Preference. Two weeks after the conclusion of dosing,
rats were tested in a social preference test as described previously
[8]. The social preference test apparatus consisted of a wooden
arena (1200 mm long 6 1200 mm wide 6 830 mm high) in a
room dimly illuminated by a 40 W red bulb. This enclosure was
fitted with a mesh grid floor and both walls and floor were painted
matt black. Animal behavior was recorded as in the Elevated Plus
Maze test above.
The social preference arena contained two small cages on
opposite walls (300 mm wide6 200 mm long6 200 mm deep).
One cage contained an adolescent Wistar rat that was of similar
age and weight to the test subject, but unfamiliar to the test
animal. A new caged animal was used for each test. The other
cage contained a life-sized toy rat; this was included to control for
the possibility of the subject rat visiting the caged rat purely out of
visual curiosity. Time spent within close proximity (150 mm) of the
caged rat was taken as an index of social motivation [48,49]. Social
preference and locomotor activity was measured for 10 min before
rats were returned to their home cages.
Novel Object Recognition. Novel object recognition (NOR)
testing took place 35 days after the conclusion of dosing, in an
opaque black plastic circular arena (80 cm diameter 6 51 cm
height). Rats were given repeated habituation exposures to the
testing arena for several days prior to training in the absence of
any objects. The following day rats received a paired trial
consisting of a sample trial and a test trial. During the sample trial
rats were individually placed in the arena for 3 min in the presence
of two identical objects, spaced 15 cm from the periphery on
opposite sides of the arena. The rat was then returned to a holding
cage, and after a 15 min delay the test trial was conducted. During
the test trial the rat was placed in the arena for 3 min with one
object the same as in the sample trial and a new, ‘‘novel’’ object
that was different in shape, size and texture. All objects were fixed
to the floor of the arena or heavily weighted so they could not be
moved by the rats. Between each trial, the arena and objects were
cleaned with 70% ethanol solution and air-dried, and triplicate
sets of all objects were used to ensure no odors were present or
associated with any of the objects or arena. The objects were a
plastic spray bottle and a ceramic oil burner, all painted matt
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black. Test objects, placement of the novel object and order of
testing were counterbalanced across conditions.
Scoring of object investigation was conducted from video (using
OD Log software: www.macropodsoftware.com) by an observer
who was blind as to experimental condition and the identity of the
novel object. Only active investigation (i.e. sniffing, pawing, biting)
was counted as investigation; perching on top of the object was not
counted as investigation.
Neurotransmitter and metabolite analysis. At 47 days
after the conclusion of drug treatment rats were rapidly
decapitated and their brains removed. HPLC analysis was carried
out as per Experiment 1.
Data Analysis
In Experiment 1, behavioral measures and HPLC results were
compared across the different treatment conditions using planned
contrasts with Bonferroni adjustments. The critical comparisons
were as follows:
1) VEH versus METH (both METH61 and METH610
groups), which allows determination of overall METH
effects;
2) VEH versus MMC (both MMC61 and MMC610 groups),
which allows determination of overall MMC effects;
3) METH61 versus METH610, which allows determination of
possible METH sensitization effects;
4) MMC61 versus MMC610, which allows determination of
possible MMC sensitization effects.
A significance level of P,0.0125 was used which represents the
alpha level (0.05) divided by the number of contrasts (4, Bonferroni
correction). For the autoradiography analysis, only the first two
contrasts were required (due to the exclusion of the singly-dosed
groups). These contrasts therefore used a significance level of
P,0.025 (Bonferroni correction). For Experiment 2, a simple one-
way ANOVA followed by post hoc Dunnett’s test was used to
compare each MMC group (MMC7.5, MMC15, and MMC30)
with the control (VEH) group on key behavioral and neurochem-
ical measures.
In both experiments the Levene test was employed to ensure
homogeneity of variance between groups. When this was not
satisfied a logarithmic or square root transformation of the data
was applied (in all cases, the transformation with a higher P value
on Levene’s test was used).
Results
Drug Analysis
HPLC analysis of the customs-sourced MMC utilized in both
experiments found it to have a purity of 99.6560.09% (tR
10.4 min, e¨max 258 nm).
Experiment 1
Weight gain. Weight gain measurements over the 10 day
injection period (Figure 1) showed that the MMC610 group
gained significantly less weight than a composite control group
containing all of the rats that received vehicle treatment over the
first 9 days of the experiment (VEH group, MMC61 group and
METH61 group). This composite control group was appropriate
given that the MMC61 and METH61 group had not received
any drug at the beginning of day 10 of dosing when these weight
measures were taken. No other comparisons were significant.
Locomotor Activity. The results for distance travelled in the
hour following dosing on day 1 and day 10 are presented in
Figure 2. The locomotor response of the MMC and METH
groups significantly exceeded that of the VEH group (Overall
ANOVA F4,35 = 22.72, P,0.001; both contrasts P,0.01). For
both METH and MMC, the 610 groups did not significantly
differ from the61 groups, suggesting that little if any locomotor
sensitization had developed.
Neurotransmitter Levels. HPLC results showing neuro-
transmitter and metabolite levels 60 min after the 10th day of
dosing in Experiment 1 are presented in Table 2.
Both the combined MMC and the combined METH groups
had significantly elevated levels of striatal DA relative to VEH
Table 1. The test sequence employed in Experiment 2.
Experiment Day 1 2 3 4 5 6 7 8 9 10 21 25 45 57
Dosing ! ! ! ! ! ! ! ! ! !
Elevated Plus Maze !
Social Preference !
Novel Object Recognition !
Euthanasia !
doi:10.1371/journal.pone.0045473.t001
Figure 1. Weight gain over the 10 dosing days. Adolescent rats
were given either saline injections, MMC (30 mg/kg/day) or METH
(2.5 mg/kg/day) once per day during this period. # represents a
significant difference when comparing the MMC610 group with the
combined VEH, METH61 and MMC61 groups (the latter groups had not
received their single dose of the drug at the time when the weights
were measured). The dotted line represents the mean for the combined
VEH, METH61 and MMC61 groups.
doi:10.1371/journal.pone.0045473.g001
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(Overall ANOVA F4,31 = 3.36, P,0.05; both significant contrasts
P,0.01). No other contrasts were significant for DA.
Striatal levels of HVA in the MMC61 group significantly
exceeded those of the MMC610 group (Overall ANOVA
F4,31 = 3.49, P,0.05; MMC61 vs MMC610 contrast P,0.01).
No other contrasts were significant for HVA. For DOPAC there
was an overall significant ANOVA (F4,31 = 2.77, P,0.05). There
was a non-significant trend towards depression of striatal DOPAC
in the MMC610 group relative to MMC61, an effect that did not
survive Bonferroni correction (P= 0.032, n.s.).
Striatal DA metabolism ((HVA + DOPAC)/DA) was signifi-
cantly reduced relative to VEH for both METH and MMC
groups (Overall ANOVA F4,31 = 10.78, P,0.001; both contrasts
P,0.001). No other contrasts were significant on this measure,
although again there was again a strong trend towards a greater
depression of striatal DA metabolism in the MMC610 group
relative to MMC61 group (P = 0.033, n.s.).
MMC treated rats displayed significantly diminished levels of
striatal 5-HT relative to VEH (Overall ANOVA F4,31 = 10.18,
P,0.001; contrast P,0.01). No other contrasts were significant on
this measure. No significant differences were found with striatal 5-
HIAA levels, although there was again a non-significant trend
towards 5-HIAA depression in the MMC610 group relative to the
MMC61 group (Overall ANOVA F4,31 = 3.43, P,0.05; contrast
P= 0.03, n.s.).
Striatal 5-HT metabolism (5-HIAA/5-HT) was significantly
increased in MMC groups relative to VEH (Overall ANOVA
F4,31 = 26.74, P,0.001; contrast P,0.001). 5-HT metabolism was
also significantly elevated in the MMC61 group relative to the
MMC610 group (P,0.01). No other contrasts were significant.
In the hippocampus, as with the striatum, 5-HT levels were
significantly lower in MMC groups compared to VEH (Overall
ANOVA F4,29 = 30.35, P,0.001; contrast P,0.001); no other
hippocampal 5-HT contrasts were significant. No contrasts proved
significant on hippocampal 5-HIAA levels, although there was a
non-significant trend towards elevated hippocampal 5-HIAA levels
in METH animals relative to VEH (Overall ANOVA F4,29 = 8.74,
P,0.001; contrast P,0.014, n.s.). Hippocampal 5-HT metabo-
lism was significantly elevated in MMC groups relative to VEH
(Overall ANOVA F4,29 = 32.88, P,0.001; contrast P,0.001). A
non-significant trend was apparent towards elevated hippocampal
5-HT metabolism in the MMC61 group relative to the MMC610
group (p = 0.04, n.s.).
Autoradiography Results. Results of the autoradiographic
analyses are presented in Table 3. No significant differences were
found in CLINDE binding in any region examined.
Figure 2. Distance travelled. Locomotor activity in the hour following dosing in rats given their first or tenth daily dose of methamphetamine
(METH, 2.5 mg/kg) or mephedrone (MMC, 30 mg/kg). Error bars represent + S.E.M. On the first day (Figure 2A), the two drug treated groups
(MMC610 and METH610) travelled greater distance than the three vehicle-treated groups (P,0.01, indicated by ++). On day 10 (Figure 2B) both the
combined METH groups and the combined MMC groups travelled greater distance than the VEH group (P,0.01, indicated by *). A logarithmic
transformation was applied to the data due to heterogeneity of variance.
doi:10.1371/journal.pone.0045473.g002
Table 2. Mean (SEM) neurotransmitter and metabolite levels
in brains collected 1 h post-mortem during Experiment 1.
VEH METH61 METH610 MMC61 MMC610
Striatum
Dopamine 4690 (313) 5985 (445)1 6766 (269)1 6753 (621)2 5825 (479)2
HVA 588 (39) 538 (38) 646 (41) 674 (67)3 453 (45)3
DOPAC 665 (28) 612 (43) 680 (51) 635 (38) 492 (50)
HVA+DOPAC/DA 0.27 (0.02) 0.19 (0.01)1 0.20 (0.01)1 0.20 (0.01)2 0.16 (0.01)2
5-HT 305 (23) 338 (30) 359 (17) 218 (14)2 203 (23)2
5-HIAA 719 (46) 798 (61) 812 (38) 747 (46) 594 (38)
5-HIAA/5-HT H 2.38 (0.10) 2.38 (0.06) 2.27 (0.04) 3.43 (0.17)2 33.02 (0.10)2 3
Hippocampus
5-HT 99 (7) 101 (5) 104 (5) 52 (5)2 53 (4)2
5-HIAA 172 (9) 197 (7) 190 (9) 155 (7) 141 (9)
5-HIAA/5-HT H 1.69 (0.11) 1.93 (0.05) 1.85 (0.07) 3.06 (0.17)2 32.67 (0.08)2 3
Data are mean (S.E.M.). Neurotransmitter and metabolite levels are expressed in
ng/g wet tissue, metabolism measures are expressed as ratios. VEH= vehicle
injections only; METH61= 2.5 mg/kg methamphetamine I.P. once;
METH610 = 2.5 mg/kg methamphetamine I.P. once/day for ten days;
MMC61= 30 mg/kg mephedrone I.P. once; MMC610 = 30 mg/kg mephedrone
I.P. once/day for ten days.
Hindicates heterogeneity of variance in untransformed data.
1sig. diff. (P,0.01) comparing VEH to combined METH groups;
2sig. diff. (P,0.01) comparing VEH to combined MMC groups;
3sig. diff. (P,0.01) comparing MMC61 to MMC610 groups.
doi:10.1371/journal.pone.0045473.t002
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Experiment 2
Long-term residual effects of MMC. In Experiment 2,
none of MMC-treated groups significantly differed from the VEH
group in weight gain either during dosing (F3,37 = 0.29, P= 0.83)
or during the post-dosing period (F3,37 = 0.33, P= 0.80). None of
the MMC-treated groups differed from the VEH group on the
elevated plus maze or social preference tests (results summarized in
Figure 3).
Significant differences between groups were obtained on the
novel object recognition test (Figure 4), with the MMC30 group
alone showing significantly impaired memory relative to the VEH
group (Overall ANOVA on preference for novel object
F3,43 = 4.43, P,0.01; Dunnet’s contrast on MMC30 against
VEH P,0.05). None of the MMC-treated groups differed from
the VEH group in total inspection time during the novel objection
recognition test (F3,43 = 0.86, P= 0.47).
Neurotransmitter Levels. HPLC results from Experiment 2
are presented in Table 4. None of the MMC-treated groups
differed from the VEH group in DA and 5-HT levels or in 5-
HIAA/5-HT or HVA+DOPAC/DA ratios in the striatum or
hippocampus.
Discussion
Overall, the MMC treatment utilized in these experiments (up
to ten daily doses of up to 30 mg/kg MMC I.P.) was well tolerated
by all rats. This dosing regimen produced no lethality, no apparent
distress and only a very subtle effect on body weight with repeated
MMC dosing in Experiment 1 (but not in Experiment 2). The
choice of dose was based upon prior work [8] with preliminary
observations suggesting that MMC was roughly tenfold less potent
than METH in stimulating locomotor hyperactivity. The 30 mg/
kg MMC dose in rats may be slightly higher than a standard
human single dose (perhaps 200–300 mg), but it is worth noting
that typical human use involves multiple doses of MMC consumed
in a single session [50], with mean per-session consumption in
regular MMC users exceeding one gram [30].
The locomotor response induced by 30 mg/kg MMC con-
firmed our prior findings of profound hyperactivity with the drug
[8]. As with our earlier study, the locomotor stimulation observed
surpassed the METH effect in magnitude, even though the dose of
METH used here was 2.5 mg/kg rather than the 2 mg/kg used in
our previous study. Locomotor hyperactivity with MMC has also
been observed with a relatively low dose (3 mg/kg, but not 1 mg/
kg S.C.) of the drug in a previous study [9].
There was no sign of behavioral sensitization in Experiment 1,
with rats on their tenth daily dose of METH or MMC showing
similar distance travelled to those given their very first dose
(Figure 2). The absence of behavioral sensitization was matched by
an equivalent lack of difference in most neurochemical parameters
in rats given single versus repeated dosing (Table 2). Sensitization
phenomena with amphetamines and MDMA can be relatively
subtle and are influenced by factors such as context, age and strain
of animal, dose level and dose intermittency, baseline habituation
and the behavioral measure employed [51]. While researchers
have frequently found robust sensitization effects in METH
treated animals, these findings often utilize dosing regimens
substantially in excess of those given in the current study (e.g.:
[52,53]). Sensitization effects are also demonstrated through
behavioral measures other than simple distance travelled; for
example, Wallace et al. [53] used proportion of time in stereotypy
rather than total locomotor behavior. It therefore remains possible
that the treatments utilized in the current experiment may elicit
some degree of behavioral sensitization that is not captured by
simple locomotor measures.
Age factors may also have a substantial effect on behavioral
sensitization; while stimulant drug treatment can induce locomo-
tor sensitization in both adult and adolescent rats, these effects are
generally less reliable in adolescents [54]. The temporal pattern of
drug treatment may have also contributed to the lack of a clear
sensitization effect, as a daily schedule of drug treatment (used in
the current study) generally produces less sensitization than a
pattern involving multiple periods of drug consumption separated
by drug-free ‘‘holiday’’ periods [54,55].
MMC triggered substantial alterations in DA and 5-HT systems
in the striatum and the 5-HT system in the hippocampus
measured 1 h post dosing. These results are to a certain extent
predictable from recent in vivo and in vitro studies [9,10,11] that
demonstrate the strong affinity of MMC for DAT and SERT and
the modulation of extracellular DA and 5-HT in the nucleus
accumbens. Our results, using an ex vivo snapshot of regional
neurotransmitter content, indicate that at 1 h following 30 mg/kg
MMC, whole tissue concentrations of DA were significantly
elevated in the striatum while DA metabolism (indexed by
measuring HVA+DOPAC/DA) was significantly decreased. In
contrast 5-HT levels were significantly decreased by MMC and 5-
HT metabolism (indexed by 5-HIAA/5-HT) increased. By
comparison, METH had similar effects to MMC on DA and
DA metabolism but no significant impact upon 5-HT tissue levels
or 5-HT metabolism. Hippocampal 5-HT and 5-HT metabolism
effects with MMC were similar to those seen in the striatum.
The contrasting patterns of change seen in DA and 5-HT
systems 1 h after MMC dosing (DA increased, DA metabolism
decreased; 5-HT decreased, 5-HT metabolism increased) suggests
that MMC may trigger a brief but vigorous efflux of 5-HT,
thereby inducing the short-lived euphoric rush that characterizes
the initial phase of the drug experience [50,56]. This is in
agreement with microdialysis observations of a very rapid and
sudden peak in 5-HT levels approximately 20 min after MMC
administration [9]. Presumably this 5-HT is then rapidly
metabolized to 5-HIAA to produce the pattern of increased 5-
HT metabolism and decreased 5-HT levels observed in the
present study 1 h after dosing. The dramatic reduction of 5-HT
levels following MMC dosing suggests the possibility of exhausting
the 5-HT response with closely-spaced multiple doses [10]. This
may explain user reports of a substantial weakening of the initial
euphoric effect following repeated dosing within a single session
[50]. An MDMA-like inhibition of tryptophan hydroxylase could
also form part of the explanation for this rapid partial tolerance
Table 3. Autoradiographic analysis of [125I]CLINDE binding in
repeatedly-dosed animals compared to control.
VEH METH610 MMC610
Anterior Thalamus 11.89 (1.01) 9.52 (1.77) 10.61 (1.57)
Hippocampus 10.85 (0.86) 8.54 (1.52) 9.68 (0.79)
Nucleus Accumbens 9.57 (1.02) 6.16 (1.09) 7.76 (1.04)
Olfactory Tubercle 9.40 (1.50) 9.26 (1.58) 9.25 (1.05)
Striatum 9.08 (0.93) 7.49 (1.55) 11.47 (1.33)
Substantia Nigra 15.67 (1.92) 16.18 (2.85) 11.56 (2.45)
Data are mean (S.E.M.). Values are nCi/mg specific binding of [125I]CLINDE.
VEH= vehicle injections only; METH610 = 2.5 mg/kg methamphetamine I.P.
once/day for ten days; MMC610 = 30 mg/kg mephedrone I.P. once/day for ten
days. Brain tissue harvested 1h after final dose.
doi:10.1371/journal.pone.0045473.t003
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Figure 3. Residual MMC effects. A. Open arm time, and B. Distance travelled on the Elevated Plus Maze which was run 11 days after the
conclusion of dosing. C. Investigation time for the fake rat and the real rat, and D. Distance travelled in the Social Preference test which was run 15
days after the conclusion of dosing. Error bars represent + S.E.M. No significant differences were found between groups on either test. VEH= saline
1 ml/kg I.P., MMC7.5= 7.5 mg/kg mephedrone I.P., MMC15= 15 mg/kg mephedrone I.P., MMC30=30 mg/kg mephedrone I.P.
doi:10.1371/journal.pone.0045473.g003
Figure 4. Performance on the Novel Object Recognition test. A. Percentage of total investigation time spent investigating the novel object
(dotted line represents chance performance). B. Time spent inspecting familiar and novel objects. Test was conducted 35 days after the conclusion of
dosing and 15 min after a 3 min training exposure. See text for further details. Error bars represent + S.E.M.; ** represents significant difference from
VEH (Dunnett’s test, P,0.01). VEH= saline 1 ml/kg I.P., MMC7.5 = 7.5 mg/kg mephedrone I.P., MMC15= 15 mg/kg mephedrone I.P., MMC30= 30 mg/
kg mephedrone I.P.
doi:10.1371/journal.pone.0045473.g004
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[57]. As disturbances of 5-HT function have been repeatedly
shown to be linked to risk of suicide [58], there may be a
connection between this finding and the apparently high levels of
suicide amongst MMC-linked fatalities [59].
In contrast, the increase in DA levels may represent a more
gradual and sustained effect of the drug. This could be achieved by
increased release of DA in some brain areas [9] coupled to an
inhibition of DA metabolism and reuptake. A specific inhibition of
monoamine-oxidase B (involved in DA breakdown) but not
monoamine oxidase A (involved in 5-HT breakdown) by MMC
is one plausible explanation of this effect. Cathinone (as well as
some of its derivatives) appears to have such an effect, although
MMC may not necessarily do so [60,61].
The dopaminergic effects of MMC may be responsible for the
substantial locomotor stimulation, which is frequently reported by
users to be of longer duration than the initial euphoric effects of
the drug [50]. Again, this agrees with recent findings that MMC
induces a rapid and substantial increase in both DA and 5-HT in
the nucleus accumbens, but that the 5-HT response is greater in
magnitude and shorter in effect [9]. Previous work in this
laboratory demonstrated a massive induction of the Fos protein
throughout the striatum following a single dose of MMC [8]. The
combination of the psychological appeal of the short-lived initial
euphoric impact and craving effects associated with activation of
the mesolimbic DA pathway provide the foundation for a
powerfully addictive drug that is readily self administered by rats
via the intravenous route [10].
Interestingly, there was no significant difference in DA or 5-HT
levels with single versus repeated administration of either drug.
However, MMC caused a significantly greater reduction in 5-HT
metabolism in the repeated MMC group than the single treatment
group, suggesting the induction of subtle neuroadaptations in 5-
HT systems with repeated MMC. In addition, the repeated MMC
group showed lower HVA and a strong trend towards lower
DOPAC than the single group suggesting similar subtle alterations
in brain DA metabolism with repeated MMC.
No signs of neuroinflammation were evident with MMC or
METH using [125I]CLINDE autoradiography. This is in accord
with the general absence of overt brain injury noted by other
researchers with MMC [23]. While a more rigorous dosing
regimen of MMC may induce an inflammatory response, such an
approach is likely to require dosing levels well beyond those seen in
typical human use. The absence of inflammation in the METH
group was not unexpected. Although METH has been clearly
shown to be capable of inducing an inflammatory response
[40,41], such a response typically involves doses substantially in
excess of those used here, administered in ‘‘binge’’ fashion and
sometimes with elevated ambient temperatures.
Experiment 2 was also orientated around determining possible
lasting changes in 5-HT and DA following MMC. A recent study
[10] reported a persistent decrease in brain 5-HT at 7 days
following a binge treatment regimen of MMC (4610 or 25 mg/
kg per day for four days). However, other investigators have
failed to find any persistent neurochemical impact of MMC
dosing with fairly short duration dosing protocols [12,23].
Comparable drugs (e.g. MDMA, METH) can induce lasting
alterations in a variety of neurotransmitter systems when
administered at high dose levels [62]. However, after a 57 day
washout, our analysis revealed no significant differences in any
neurochemical measures in rats treated with MMC daily for 10
days relative to controls.
The discrepancy between this finding and previous results by a
different group [10] may reflect the repeated within-session binge
administration used by these authors and the shorter interval after
dosing at which 5-HT depletion was assessed (1 week). In addition,
the rats used in the earlier study were maintained at an elevated
temperature ($27uC) throughout treatment, which can have a
strong influence on stimulant-induced neurotoxicity [63].
In the current study, no lasting behavioral effects of repeated
MMC treatment were evident in measures of anxiety (elevated
plus maze) and social preference. However, the novel object
recognition test did reveal a clear deficit in the 30 mg/kg MMC
pre-treated group when tested 36 days after drug treatment. In a
recent human study [30] MMC users displayed impaired prose
recall compared to controls. At present, the cause of this
impairment in recognition memory is unknown, although the
strong effect of MMC on hippocampal 5-HT and 5-HT
metabolism does suggest the possibility of specific toxicity driven
by downstream neuroadaptations occurring in response to this
initial perturbation of 5-HT. To our knowledge, the present result
represents the first behavioral demonstration in rats of a lasting
negative effect of MMC consumption and may provide a useful
guide to further research into potential MMC neurotoxicity in
both laboratory animals and human users.
In summary, our data confirm powerful acute effects of MMC
on monoaminergic neurotransmitter systems. However, 10 days
of chronic MMC did not appear to induce any overt injury or
lasting alteration in DA or 5-HT systems. Despite this, the
impairment of recognition memory observed in high-dose
animals more than a month after the cessation of drug provides
reason to suspect that MMC may still induce major neuroa-
daptations, albeit of a subtle nature not detected in the current
study. Confirming this finding via replication and pursuing a
mechanistic explanation for the observed impairment are obvious
priorities for future studies.
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Table 4. Mean (S.E.M.) neurotransmitter and metabolite
levels 47 days after final dose.
VEH MMC(7.5) MMC(15) MMC(30)
Striatum
Dopamine 8256 (1006) 8731 (1239) 9067 (1082) 8487 (621)
DOPAC 827 (98) 802 (95) 855 (115) 824 (77)
HVA 678 (85) 674 (86) 689 (93) 658 (57)
HVA+DOPAC/DA 0.18 (0.01) 0.18 (0.16) 0.17 (0.16) 0.18 (0.16)
5-HT 301 (31) 303 (37) 377 (48) 300 (21)
5-HIAA 477 (56) 464 (58) 529 (58) 473 (38)
5-HIAA/5-HT 1.57 (0.05) 1.54 (0.04) 1.43 (0.04) 1.58 (0.06)
Hippocampus
5-HT 140 (8) 127 (6) 125 (9) 130 (5)
5-HIAA 209 (9) 210 (14) 193 (12) 208 (12)
5-HIAA/5-HT 1.51 (0.06) 1.67 (0.14) 1.62 (0.16) 1.62 (0.11)
Data are mean (S.E.M.). Neurotransmitter and metabolite levels are expressed in
ng/g wet tissue, metabolism measures are expressed as ratios. VEH= saline
1 ml/kg I.P., MMC(7.5) = 7.5 mg/kg mephedrone I.P., MMC(15) = 15 mg/kg
mephedrone I.P., MMC(30) = 30 mg/kg mephedrone I.P. All animals were dosed
once per day for ten consecutive days followed by a 47 day washout period. No
significant differences were found between treatment groups.
doi:10.1371/journal.pone.0045473.t004
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